SLC16A3 and cancer: MCT1 and MCT4 overexpression and co-overexpression with CD147, are considered a hallmark of cancer (1–6), indicating the inactivation of these transporters with specific inhibitors or by targeting their chaperone CD147 (11–14), as a promising strategy for cancer therapy (1–5, 8, 22, 26–31).